SCHEMBL3619787

SCHEMBL3619787

COc1cc(CN2CCCC2)c2ccn(S(=O)(=O)c3ccccc3)c2c1

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 18/20 0.58
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
TP53 P04637 1/20 0.52
POLB P06746 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3622810 0.98 HTR6 (0.58) HTR6CYP3A4CYP2D6MEN1KMT2A
Trifluoroacetic Acid SCHEMBL3620333 0.92 HTR6 (0.51) HTR6CYP3A4CYP2D6MEN1KMT2A
SCHEMBL3625780 0.92 HTR6 (0.70) HTR6CYP3A4CYP2D6
SCHEMBL3620062 0.91 HTR6 (0.64) HTR6CYP3A4CYP2D6MEN1KMT2A
SCHEMBL3619815 0.91 HTR6 (0.69) HTR6CYP3A4CYP2D6MEN1KMT2A
Trifluoroacetic Acid SCHEMBL3624799 0.90 HTR6 (0.51) HTR6CYP3A4CYP2D6MEN1KMT2A
SCHEMBL3616898 0.85 HTR6 (0.51) HTR6CYP3A4CYP2D6
Trifluoroacetic Acid SCHEMBL3623292 0.85 HTR6 (0.56) HTR6CYP3A4CYP2D6MEN1KMT2A
Trifluoroacetic Acid SCHEMBL3620855 0.85 HTR6 (0.61) HTR6CYP3A4CYP2D6
SCHEMBL3619791 0.84 HTR6 (0.52) HTR6CYP3A4CYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US claimed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US claimed
EP-2046741-B1 INDOLES AS 5-HT6 MODULATORS PROXIMAGEN LTD (GB) 2012-10-31 EP disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
US-7812017-B2 4-substituted indole and indoline compounds BIOVITRUM AB (PUBL.) (SE) 2010-10-12 US disclosed
EP-2046741-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (publ) (SE) 2009-04-15 EP disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
US-20080032968-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-02-07 US disclosed
WO-2008003703-A1 INDOLES AS 5-HT6 MODULATORS BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032968-A1 New compounds HTR6, HTR1B, HTR1A HTR6 1/4885CYP3A4 405/4885CYP2D6 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.